Combination paclitaxel and vinorelbine therapy: In vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines

International Journal of Oncology

Volumn 14, Issue 5, 1999, Pages 999-1006

  Culine, Stephane ^a   Roch, Isabelle ^a   Pinguet, Frederic ^a   Romieu, Gilles ^a   Bressolle, Francoise ^b  

^a CENTRE VAL D AURELLE   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Chemotherapy; Metastatic breast cancer; Paclitaxel; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; NAVELBINE; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ARTICLE; BREAST TUMOR; CELL CULTURE; CELL DIVISION; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; FEMALE; HUMAN; METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0033127001     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.5.999     Document Type: Article

References (25)

1. Holmes FA, Walters RS, Thierault RL, Foman AD, Newton LK, Raber MN, Buzdar AU, Wiley J and Hortobagyi GN: Phase II trial of Taxol: an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
2. Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S and Norton L: Paclitaxcl and recombinant human granulocyte-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943-1951, 1993.
3. Seidman AD, Reichman BS, Crown JPA, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Souhrada M, Onetto N, Arbuck S and Norton L: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159, 1995.
4. Rowinski EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1993.
5. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stcfanelli M, Valagussa P and Bonadonna G: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995.
6. Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R and Speyer J: Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 14: 1993-1999, 1996.
7. Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Sartorius S, Chen TL, Bowling K and Rowinsky E: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14: 783-791, 1996.
8. R on tubulin and associated proteins. Semin Oncol 16 (Suppl. 4): 9-14, 1989.
9. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, Lecourt L and Montcuquet P: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245-1252, 1993.
10. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J and Hohneker J: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13: 2722-2730, 1995.
11. Roch I, Bressolle F and Pinguet F: In vitro schedule-dependent interaction between paclitaxel and vinorelbine in A2780 parenteral and multidrug-resistant human ovarian cancer cell lines. Int J Oncol 11: 1379-1385, 1997.
12. Iaffaioli RV, Facchini G, Caponigro F, Illiano A, Gentile M, Gravina A and Muto P: Phase I study of vinorelbine and paclitaxel in small-cell lung cancer. Ancer Chemother Pharmacol 41: 86-90, 1997.
13. Michelotti A, Gennari A, Salvadori B, Tognoni A, Tibaldi C, Baldini E and Conte PF: Paclitaxel and vinorelbine in anthracyclin-pretreated breast cancer: a phase II study. Ann Oncol 7: 857-860, 1996.
14. Tortoriello A, Facchini G, Caponigro F, Santangelo M, Benassai G, Persico G, Citarella A, Carola M, Marzano N and Iaffaioli RV: Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 47: 91-97, 1997.
15. Hortobagyi GN and Ibrahim N: Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Semin Oncol 23 (Suppl. 1): 53-57, 1996.
16. Skehan P, Storeng R and Scuderio G: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
17. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol 5: 85-91, 1979.
18. Miller AB, Hoogstraten B and Straquet M: Reporting results of cancer treatment. Cancer 147: 207-214, 1981.
19. Rowinsky EK, Citardi MJ, Noe DA and Donehower RC: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the microtubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 727-733, 1993.
20. R) combined with cisplatin and alkylators in human cancer cells. Oncol Res 6: 25-31, 1994.
21. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schröder J and Seeber S: Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A: 92-97, 1995.
22. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y and Adachi KI: Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74: 704-710, 1996.
23. Speicher LA, Barone L and Tew KD: Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52: 4433-4440, 1992.
24. Chou TC, Motzer RJ, Tong Y and Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524, 1994.
25. Knick VC, Eberwein DJ and Miller CG: Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 87: 1072-1077, 1995.